Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novartis Challenger To Alexion Advances In Rare Kidney Disease

Ultomiris Head-to-Head Planned

Executive Summary

First-in-class iptacopan could help Novartis expand into kidney disease, and take on Alexion’s blockbuster rare disease franchise.

You may also be interested in...



New Pure Play Novartis Vows To Up Its Game – With Help From In-House Challenger Ronny Gal

Having finally confirmed the Sandoz spin-off, Novartis will become a 'pure play' pharma company and focus on picking bigger blockbuster winners from both internal and external pipelines. CEO Vas Narasimhan talked details at an investor day in Basel.

Alnylam/Regeneron Face Crowded IgA Nephropathy Field, But Combinations Likely

Phase II data position cemdisiran well for Phase III, but several agents are already well ahead. However, Alnylam foresees a polypharmacy approach.

Novartis’s John Tsai On The Four Philosophies Driving R&D

Scrip spoke with global development head and chief medical officer John Tsai about the factors Novartis considers when it decides which R&D programs to advance, including externally sourced assets. 

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC144489

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel